• >20 years of experience in global healthcare and medical technology across the USA, Australia, Europe, and Asia.​
• Executive position at Universal Biosensors in Australia. At the time of departure, UBI ended Q2 FY19 with A$50.9 million closing cash balance to execute the next phase of the business.
• Held Senior Vice President, Corporate Account Management position at Siemens Healthcare in Germany.
• Prior to joining Adherium, worked as a consultant for global healthcare clients in the USA and China focused on the COVID pandemic.
• Extensive experience in strategic-growth platforms, commercial development and cross-border expansion, customer service, and business improvement and turnaround.

• Qualified Chartered Accountant and established company executive with 25 years finance, operations and commercial experience.
• Extensive experience in ASX-listed and private entities in healthcare, health technology and manufacturing.
• ​Held senior position at Ramsay Health Care where he had a key role in setting up its pharmacy division and served as CFO/COO at MediSecure delivering real-time prescription monitoring services.

• >25 years of information technology governance and leadership, solution innovation and realization across Australia and internationally including Europe, USA and Asia​
• Executive positions in acute healthcare sector and 10 years with Tunstall Healthcare, both globally and Australasia​
• Extensive experience with Remote Patient and Chronic Disease platform, and product, development and market release​
• Geoff is a Board Member and Vice Chair of Australia’s Personal Emergency Response Services Limited (PERSL), and committee member of the Medical Technology Association of Australia (MTAA)​

• >30 years experience in Digital Health & Medical Device commercialisation. Creating and building successful teams​
• Executive positions in Medtronic, Olympus Medical and Vice President, AliveCor Ltd, EMEA and OUS globally

• Certified regulatory and quality professional with >20 years of health technology product development and commercial experience across the US, Europe, Asia, Australia and New Zealand​
• Leadership and advisor positions with private and publicly traded health technology companies

• Certified Human Resources professional with over 15 years’ experience
• Extensive experience in operational leadership, developing and implementing initiatives that promote long-term goals, future proofing businesses and supporting transformational changes, innovation, and the complexities of attracting talent on the international market
• Experience across a range of industries including medical devices, consumer electronics, management consulting, manufacturing, construction, horticulture, and retail in New Zealand, Australia, the United States, Asia, and Europe

Therese has 12 years’ experience in the medical device industry in both New Zealand and Australia across a range of medical devices including in-vitro diagnostic instruments, respiratory-assist devices, rehabilitation devices, implantable devices, wearables, and connected devices. She has worked with companies such as Fisher & Paykel, Planet Innovation, and Rex Bionics.

With her background in ISO 13485 – regulated environments, working with products marketed in the US and Europe, she brings a strong focus on quality, safety, and reliability.

Therese graduated from the University of Auckland with a Bachelor of Engineering (Hons) in Bioengineering, and a PhD in Bioengineering.

Nigel has over 40 years’ experience in manufacturing, engineering and operations, starting his career with British Aerospace where he worked in the UK before emigrating to New Zealand in 1995, and has held a number of senior and executive positions with a number of technology companies including OSCMAR International Ltd, Cubic Defense (NZ) Ltd, Boeing (USA), and Dyson Ltd (Malaysia).

Most recently Nigel was Vice President of Global Operations for NextWindow Ltd a New Zealand Technology company. For the last five years of the role Nigel was based in Singapore, setting up and developing an office to support operations across Asia. Nigel was responsible for the entire supply chain, procurement, manufacturing and New Product Introduction (NPI), and had a team spread across Asia and New Zealand.

Nigel graduated from the University of Huddersfield (UK) with a 1st Class Bachelor of Engineering in Computer Aided Engineering and is a Chartered Engineer and a member of the IET.

Santhosh has 15 years’ experience in managing IT Systems and Operations for electronics and healthcare industries. Most recently Santhosh worked as IT Manager for PowerbyProxi, a New Zealand wireless charging technology company acquired by Apple. Before that Santhosh was the IT and Operations Manager for NextWindow, a New Zealand touchscreen technology company.

Santhosh has a post graduate diploma from Auckland University of technology and bachelor of electronics and computer hardware degree from Mahatma Gandhi University, India. Santhosh is a certified AWS Solutions Architect and Microsoft Solutions Associate.  

Appointed on 25 February 2022

Mr Panaccio is currently on the boards of ASX and NASDAQ listed Avita Therapeutics Inc. (Non-executive Chairman from July 2014), ASX50 company Sonic Healthcare Limited, one of the world’s largest medical diagnostics companies (Non-executive Director from June 2015), and ASX-listed Rhythm Biosciences Limited (Non-executive Director from August 2017).

He is also a Non-executive Director of Unison Housing Limited, VGI Health Technology Limited, NeuralDX Limited (Non-executive Chairman from March 2019) and Haemokinesis Limited (from July 2021).

Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology for ten years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the Executive Chairman of Health Networks Australia until 2017. He was also a Non-executive Director of ASX-listed Genera Biosystems Limited from November 2010 until 28 June 2019 (Chairman from July 2011 until 28 June 2019).

Mr Panaccio holds a Bachelor of Economics from Monash University and is a Member of the Australian Institute of Company Directors.

Appointed on 17 April 2015

Mr Curnock Cook was formerly head of the life science private equity team at Rothschild Asset Management in the UK and an active investor in the Australian life science sector. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook has specialised in creating value in emerging biotech enterprises, through active participation with management. He has served on over 40 boards in various roles, including chair of private and public biotechnology companies listed on NASDAQ, LSE, TSX and ASX.

Mr Curnock Cook received his MA in Natural Sciences from Trinity College in Dublin, Ireland. He is currently Managing Director of BioScience Managers (manager of a major shareholder in Adherium) and sits on the board of Avita Medical, Rex Bionics Pty, Summatix Pty Ltd, and SeaDragon Ltd as well as a number of private UK and US based companies.

Mr Curnock Cook was previously a director of Bioxyne Limited and Phylogica Limited. He has held no other Australian public company directorships in the last three years.

Appointed on 17 December 2015

Dr Hunter has extensive experience in commercialising medical device technologies. He co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of CEO in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ. Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor, including the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug- Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter. Combined, these products have generated revenues of over $12 billion and have helped the lives of over 15 million patients globally.

He is currently President and CEO of Canary Medical Inc and formerly Correvio Pharma Corp (NASDAQ: CORV). Dr Hunter is also a Director of Rex Bionics and an Industry Expert Advisor for BioScience Managers (manager of a major shareholder in Adherium). He has previously served as a director of Epirus Biopharmaceuticals (NASDAQ: EPRS) and Union Medtech.

Dr Hunter completed his BSc from McGill University and a MSC and MD from the University of British Columbia. Dr Hunter served as a practising physician in British Columbia for five years. Dr Hunter held no other Australian public company directorships in the last three years.

Appointed on 20 July 2015

Mr McHarrie is a company director and adviser in the health and life sciences sectors with over 25 years’ experience. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit, a life sciences private equity group investing in early stage biotechnology and healthcare companies. Outside his role at Adherium, he is currently an advisor to BioScience Managers (manager of a major shareholder in Adherium) and a director at Pharmamark Nutrition (nutritional foods).

Mr McHarrie is a Fellow of the Institute of Chartered Accountants Australia and New Zealand. He holds a Bachelor of Commerce from the University of Western Australia and is a graduate member of the Australian Institute of Company Directors. Mr McHarrie has held no other Australian public company directorships in the last three years.

As noted, as an advisor to BioScience Managers, Mr McHarrie has an association with a significant shareholder of the Company. The board of directors is of the opinion that this does not compromise Mr McHarrie’s independence as to the best of the board’s knowledge he is not involved in decision making by BioScience Managers and the value of the advisory services provided is not material.

Appointed on 13 May 2021

George has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a significant shareholder.

In addition to his role at Trudell, George is an active investor in and Director of several medical device and e-health / connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. He was also a lead investor and a former Director of Vanrx Phamasystems, which was recently acquired by Cytiva Life Sciences.

George has been responsible for the marketing of new drug delivery technologies to medical opinion leaders and major pharmaceutical companies. This has included collaboration with business and clinical partners in the design and co-ordination of clinical studies. He has also been granted several US and international patents for medical devices for drug delivery and minimally invasive surgery.

He holds an MBA from the Richard Ivey School of Business, Western University, London (ON) where he currently serves on the Advisory Board of the Lawrence National Centre for Policy and Management.